This section discusses the role of anti-CTLA-4 and anti-PD-1/PD-L1 mAbs, as well as novel immune checkpoints (anti-LAG-3 and anti-TIM-3), in CRC. This evidence concerns the gene PDCD1 and colorectal carcinoma.